SARS-CoV-2 Vaccine Strain Selection: Guidance From Influenza

J Infect Dis. 2022 Dec 28;227(1):4-8. doi: 10.1093/infdis/jiac454.

Abstract

When first approved, many hoped that the SARS-CoV-2 vaccine would provide long-term protection after a primary series. Waning of immunity and continued appearance of new variants has made booster inoculations necessary. The process is becoming increasingly similar to that used for annual updating of the influenza vaccine. The similarity has become even more apparent with selection of BA.4/BA.5 as the Omicron strain of the updated bivalent (Original + Omicron) COVID-19 vaccines. It is hoped that, if COVID-19 develops winter seasonality, SARS-CoV-2 vaccines will require only annual review to determine if updates are necessary. Recommendations on whom should receive the booster would be based on conditions at that time.

Keywords: COVID-19; SARS-CoV2 vaccines; influenza; influenza vaccines; mRNA vaccines; vaccine effectiveness.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Humans
  • Influenza Vaccines*
  • Influenza, Human* / prevention & control
  • SARS-CoV-2

Substances

  • Influenza Vaccines
  • COVID-19 Vaccines